|
|
 | | | |
- close
- close
- close
- close
| |||||||||
ABII » Topics » We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business.This excerpt taken from the ABII 10-K filed Mar 12, 2010. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Executive Chairman, and Bruce J. Wendel, Chief Executive Officer. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. This excerpt taken from the ABII 10-Q filed May 8, 2009. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Executive Chairman, Leon O. Moulder, Chief Executive Officer and President, David O’Toole, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Dr. Edward Geehr, Executive Vice President of Operations, Neil P. Desai, Senior Vice President of Global Research and Development, Lex H.T. Van Der Ploeg, Senior Vice President of Integrative Medicine and Translational Science, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. These excerpts taken from the ABII 10-K filed Mar 6, 2009. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, David O’Toole, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Senior Vice President of Research and Development, Lex H.T. Van Der Ploeg, Senior Vice President of Integrative Medicine and Translational Science, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. We depend heavily on the principal members of our management and research and development teams, the loss We depend heavily on the principal members of our management and research and development teams, other personnel, which may adversely affect our ability to attract and retain key personnel. We also must continue to attract and motivate employees and keep them focused on our strategies and goals. process of integrating an acquired business, technology or product may result in unforeseen operating difficulties and expenditures and may require significant management attention that would otherwise be available for ongoing development of our existing business. In addition, we may not be able to maintain the levels of operating efficiency that any acquired company achieved or might have achieved separately. Successful integration of the companies that we may acquire will depend upon our ability to,
28 Table of Contents
This excerpt taken from the ABII 10-Q filed Nov 14, 2008. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, David O’Toole, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. This excerpt taken from the ABII 10-Q filed Aug 14, 2008. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, David O’Toole, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. This excerpt taken from the ABII 10-Q filed May 15, 2008. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, Lisa Gopala, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. This excerpt taken from the ABII 10-K filed Mar 31, 2008. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, Lisa Gopala, Chief Financial Officer, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives.
30
Table of ContentsThis excerpt taken from the ABII 10-Q filed Dec 20, 2007. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, Lisa Gopalakrishnan, Chief Financial Officer, Carlo Montagner, President of the Abraxis Oncology division, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” Only Mr. Montagner and Ms. Gopalakrishnan have employment agreements with us. The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives.
38
Table of ContentsThis excerpt taken from the ABII 8-K filed Nov 8, 2007. We depend heavily on the principal members of our management and research and development teams, the loss of whom could harm our business. We depend heavily on the principal members of our management and research and development teams, including Dr. Patrick Soon-Shiong, Chief Executive Officer, Lisa Gopalakrishnan, Chief Financial Officer, Carlo Montagner, President of the Abraxis Oncology division, Bruce Wendel, Executive Vice President of Corporate Operations and Development, Neil P. Desai, Vice President of Research and Development, and Nicholas Everett, Chief Scientist, Drug Discovery. Each of the members of the executive management team is employed “at will.” Only Mr. Montagner and Ms. Gopalakrishnan have employment agreements with us. The loss of the services of any member of the executive management team may significantly delay or prevent the achievement of product development or business objectives. | EXCERPTS ON THIS PAGE:
|
| |||||||
